BioSpace News Archive

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Ladenburg Thalmann is hosting an R&D Showcase webinar about cancer therapy-related diarrhea (CTD) on September 29, 2021 from 1:00 p.m. to 2:10 p.m. Eastern.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new clinical data on ADVM-022 intravitreal (IVT) injection gene therapy from the OPTIC trial in wet age-related macular degeneration (wet AMD) and the INFINITY trial in diabetic macular edema (DME) at upcoming medical conferences.

CGBIO, NDR Medical Technology, forge a partnership in a move to introduce puncture robot technology and collaborate in clinical studies.

On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing’s for QuadraMune™, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-191.

Harbour BioMed (“HBM”, HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first dosing of first patient in registrational phase III trial for the treatment of generalized myasthenia gravis (gMG).

Ambys Medicines, a cell and gene therapy company focused on transforming the treatment of severe liver disease by unlocking the full potential of hepatocyte transplantation, today announced their presentation highlighting the development of a first-of-its-kind bioreactor manufacturing platform.

Additionally, the companies are submitting non-dilutive grants that support combining their technologies in preclinical and clinical studies for various conditions related to central nervous system damage.

Scientists have created a new test to measure antibodies in girls who have received a vaccine for human papilloma virus, the leading cause of cervical cancer in women.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that it will host a virtual and in-person R&D Day on Tuesday, October 12th, 2021 at 4:00 p.m. CEST/ 10:00 a.m. EDT, being hosted in Paris.

Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Sanofi has selected it as a limited distribution partner for Nexviazyme® (avalglucosidase alfa-ngpt).